Company Profile: Tenaya Therapeutics
Background
Tenaya Therapeutics is a clinical-stage biotechnology company founded in 2016 by leading cardiovascular scientists from the Gladstone Institutes and the University of Texas Southwestern Medical Center. The company is dedicated to discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Tenaya's mission is to change the treatment paradigm for heart disease, aiming to improve and extend the lives of individuals affected by these conditions.
Key Strategic Focus
Tenaya Therapeutics focuses on advancing gene therapies for rare genetic disorders and more prevalent heart conditions through three interrelated product platforms:
- Gene Therapy: Developing gene replacement therapies to address specific genetic causes of heart disease.
- Cellular Regeneration: Utilizing cellular reprogramming to regenerate heart tissue and restore cardiac function.
- Precision Medicine: Employing precision medicine approaches to tailor treatments based on individual patient profiles.
The company's core objectives include targeting defined sub-populations of patients with rare or highly prevalent forms of heart disease, leveraging integrated internal capabilities such as modality-agnostic target validation, capsid engineering, and in-house manufacturing.
Financials and Funding
As of April 18, 2026, Tenaya Therapeutics' stock (TNYA) is trading at $0.7821 per share, with a market capitalization of approximately $264 million. The company has raised a total of $248 million in funding, with a valuation of $412.8 million as of January 2022. The capital has been utilized to advance its clinical-stage gene therapy programs, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Pipeline Development
Tenaya's pipeline includes several key candidates:
- TN-201: A gene therapy for MYBPC3-associated HCM, currently in Phase 1b/2 clinical trials.
- TN-401: A gene therapy for PKP2-associated ARVC, also in Phase 1b/2 clinical trials.
- TN-301: A small molecule histone deacetylase-6 (HDAC6) inhibitor for heart failure with preserved ejection fraction, in Phase 1 clinical trials.
The company is also developing an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patients with dilated cardiomyopathy and a reprogramming program for heart failure due to prior myocardial infarction.
Technological Platform and Innovation
Tenaya Therapeutics employs several proprietary technologies and scientific methodologies:
- Proprietary Technologies: The company has developed novel promoters and regulatory elements to support its gene therapy and cellular regeneration programs, aiming to ensure precise and robust expression of therapeutic payloads in different heart cell types.
- Scientific Methods: Tenaya utilizes human-induced pluripotent stem cell (iPSC) and engineered heart tissue disease models for high-throughput target identification and drug discovery. Additionally, the company employs machine learning and phenotypic screening to enhance its research capabilities.
Leadership Team
The executive team at Tenaya Therapeutics includes:
- Faraz Ali, MBA: Chief Executive Officer
- Whit Tingley, M.D., Ph.D.: Chief Medical Officer
- Kee-Hong Kim, Ph.D.: Chief Technology Officer
- Kathy Ivey, Ph.D.: Senior Vice President, Research
- Jay Vora, Ph.D., MBA: Senior Vice President, Portfolio and Program Management
- Jennifer Drimmer, J.D.: General Counsel
- Joanna Auch: Senior Vice President, People and Culture
- Matthew Pollman, M.D., M.S.: Senior Vice President, Clinical Development
- Naymisha (Isha) Patel, MBA: Senior Vice President, Quality
The scientific advisory board includes:
- Deepak Srivastava, M.D.: President, Gladstone Institutes; The Younger Family Professor, Gladstone Institute of Cardiovascular Disease; Director, Rodenberry Center for Stem Cell Biology and Medicine; Professor, University of California, San Francisco
- Eric N. Olson, Ph.D.: Scientific Founder and Member of Scientific Advisory Board
- Saptarsi Haldar, M.D.: Scientific Founder
- Benoit G. Bruneau, Ph.D.: Scientific Founder
- Sheng Ding, Ph.D.: Scientific Founder
Competitor Profile
Tenaya Therapeutics operates in a competitive landscape with several notable competitors:
- ProKidney: Focuses on regenerative medicine for kidney diseases.
- Ocugen: Specializes in gene therapies for eye diseases.
- Tectonic Therapeutic: Develops therapies for rare diseases.
- CorMedix: Concentrates on therapies for cardiovascular and infectious diseases.
- Upstream Bio: Focuses on therapies for respiratory diseases.
These competitors vary in their therapeutic areas and technological approaches but share a commitment to innovative treatments in the biotechnology sector.
Strategic Collaborations and Partnerships
Tenaya Therapeutics has established significant collaborations to enhance its research and development efforts:
- Alnylam Pharmaceuticals: Entered into a research collaboration to identify and validate novel genetic targets for cardiovascular disease therapeutics.
Operational Insights
Tenaya Therapeutics maintains a strong market position through its integrated capabilities, including proprietary disease models, capsid engineering, and in-house manufacturing. These strengths enable the company to advance its pipeline efficiently and effectively.
Strategic Opportunities and Future Directions
The company's strategic roadmap includes:
- Advancing Clinical Programs: Focusing on progressing TN-201 and TN-401 through clinical trials.
- Expanding Research Collaborations: Seeking additional partnerships to broaden its research capabilities.
- Enhancing Manufacturing Capabilities: Strengthening in-house manufacturing to support clinical and commercial supply chains.
Contact Information
- Website: www.tenayatherapeutics.com
- LinkedIn: Tenaya Therapeutics
- Headquarters: South San Francisco, California
